Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.
Semaglutide: Lower Risk of Eye Diseases in Obese, Non-Diabetic Adults
Diabetes Obes Metab
by Chen KE, Wang PC, Lin HA et al.
“Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists. Chen KE(1), Wang PC(1), Lin HA(2)(3), Lin SF(2)(4)(5)(6)(7). Author information: (1)School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. (2)Department of Emergency Medicine, Taipei Medical University Hospital, Taipei, Taiwan. (3)Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. (4)Department of Public Health, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. (5)School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan. (6)Center of Evidence-Based Medicine, Taipei Medical University Hospital, Taipei, Taiwan. (7)Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan. AIMS: To assess whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a lower incidence of age-related ocular diseases in non-diabetic older adults with overweight or obesity. MATERIALS AND METHODS: We conducted a retrospective, propensity score-matched cohort study using the TriNetX global research network. Non-diabetic, overweight or obese adults aged ≥ 60 years with an ophthalmic disease-naïve baseline were enrolled. Patients receiving liraglutide or semaglutide were matched 1:1 with users of alternative weight-loss medications (bupropion-naltrexone, phentermine-topiramate, setmelanotide or orlistat). Outcomes included up to 5-year risks of incident cataract, age-related macular degeneration (AMD), ocular hypertension, primary open-angle glaucoma (POAG) and dry eye syndrome (DES). RESULTS: After matching, 68 536 patients were included (34 268 per group). GLP-1RAs use was significantly associated with a lower 5-year risk of cataract (RR: 0.45; 95% CI, 0.40-0.50), AMD (RR: 0.33; 95% CI, 0.23-0.48), ocular hypertension (RR: 0.56; 95% CI, 0.34-0.91), POAG (RR: 0.50; 95% CI, 0.32-0.78) and DES (RR: 0.36; 95% CI, 0.31-0.42). Sensitivity analyses consistently demonstrated a lower risk across cataract subtypes, including nuclear (RR: 0.42; 95% CI, 0.37-0.48), cortical (RR: 0.37; 95% CI, 0.36-0.55) and posterior subcapsular cataracts (RR: 0.48; 95% CI, 0.26-0.91). Similar reductions were observed in retinal haemorrhage or edema (RR: 0.44; 95% CI, 0.30-0.63) and the use of dry eye-related medication (RR: 0.44; 95% CI, 0.39-0.50). CONCLUSIONS: GLP-1RAs were associated with lower risks of multiple age-related ocular conditions in non-diabetic older adults. © 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.”
Semaglutide and other GLP-1 receptor agonists just got another win in the data column. Researchers in Taiwan pulled records for over 68,000 non-diabetic, overweight, or obese adults aged 60 and up. Their goal: see if GLP-1 agonists like semaglutide change the odds of developing age-related eye diseases.
Short answer: Yes, and the numbers aren’t subtle. Semaglutide and liraglutide users saw:
55% lower risk of cataracts
67% lower risk of age-related macular degeneration
44% lower risk of ocular hypertension
50% lower risk of primary open-angle glaucoma
64% lower risk of dry eye syndrome
The study matched people using GLP-1 receptor agonists against those using other weight-loss meds like orlistat or bupropion-naltrexone. The reduction in risk held up even when breaking cataracts down into subtypes—nuclear, cortical, and posterior subcapsular—all showed solid decreases. Retinal issues like hemorrhage or edema also dropped.
Key takeaway: GLP-1 agonists, especially semaglutide, aren’t just moving the needle on metabolic health. They’re showing serious promise in protecting aging eyes, at least in this large, real-world population. This is the kind of finding that opens doors for more targeted peptide research in ocular health.
Thinking about where to source reliable research compounds? Check the vendor directory for options.
More research is coming, but this is exactly the kind of data that keeps the peptide community energized.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.